Evidence map›Paper›PMID 26657401›Full record

ArticlePloS one2015

Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.

Abdullah Mayati, Arnaud Bruyere, Amélie Moreau, Elodie Jouan, Claire Denizot, Yannick Parmentier, Olivier Fardel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Bisindole Compounds-Synthesis and Medicinal Properties.Antibiotics (Basel, Switzerland) · 2024
    Review
  3. Review
  4. Bisindolylmaleimides New Ligands of CaM Protein.Molecules (Basel, Switzerland) · 2022
    Article
  5. Article
  6. P2X7 receptor large pore signaling in avian Müller glial cells.Journal of bioenergetics and biomembranes · 2017
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Abdullah MayatiInstitut de Recherches en Santé, Environnement et Travail (IRSET), UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 35043, Rennes, France.
Arnaud BruyereInstitut de Recherches en Santé, Environnement et Travail (IRSET), UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 35043, Rennes, France.
Amélie MoreauCentre de Pharmacocinétique, Technologie Servier, 25-27 rue Eugène Vignat, 45000, Orléans, France.
Elodie JouanInstitut de Recherches en Santé, Environnement et Travail (IRSET), UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 35043, Rennes, France.
Claire DenizotCentre de Pharmacocinétique, Technologie Servier, 25-27 rue Eugène Vignat, 45000, Orléans, France.
Yannick ParmentierCentre de Pharmacocinétique, Technologie Servier, 25-27 rue Eugène Vignat, 45000, Orléans, France.
Olivier FardelInstitut de Recherches en Santé, Environnement et Travail (IRSET), UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 35043, Rennes, France.
Servier (France) · FRInserm · FRInstitut de Recherche en Santé, Environnement et Travail · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ro 31-8220 is a potent protein kinase C (PKC) inhibitor belonging to the chemical class of bisindolylmaleimides (BIMs). Various PKC-independent effects of Ro 31-8220 have however been demonstrated, including inhibition of the ATP-binding cassette drug transporter breast cancer resistance protein. In the present study, we reported that the BIM also blocks activity of the solute carrier organic cation transporter (OCT) 1, involved in uptake of marketed drugs in the liver, in a PKC-independent manner. Ro 31-8220, in contrast to other pan-PKC inhibitors such as staurosporine and chelerythrine, was thus shown to cis-inhibit uptake of the reference OCT1 substrate tetraethylammonium in OCT1-transfected HEK293 cells in a concentration-dependent manner (IC50 = 0.18 μM) and without altering membrane expression of OCT1. This blockage of OCT1 was also observed in human hepatic HepaRG cells that constitutionally express OCT1. It likely occurred through a mixed mechanism of inhibition. Ro 31-8220 additionally trans-inhibited TEA uptake in OCT1-transfected HEK293 cells, which likely discards a transport of Ro 31-8220 by OCT1. Besides Ro 31-8220, 7 additional BIMs, including the PKC inhibitor LY 333531, inhibited OCT1 activity, whereas 4 other BIMs were without effect. In silico analysis of structure-activity relationships next revealed that various molecular descriptors, especially 3D-WHIM descriptors related to total size, correspond to key physico-chemical parameters for inhibition of OCT1 activity by BIMs. In addition to activity of OCT1, Ro 31-8220 inhibited those of other organic cation transporters such as multidrug and toxin extrusion protein (MATE) 1 and MATE2-K, whereas, by contrast, it stimulated that of OCT2. Taken together, these data extend the nature of cellular off-targets of the BIM Ro 31-8220 to OCT1 and other organic cation transporters, which has likely to be kept in mind when using Ro 31-8220 and other BIMs as PKC inhibitors in experimental or clinical studies.

Indexed as

Cell Line, TumorDose-Response Relationship, DrugEnzyme InhibitorsGreen Fluorescent ProteinsHEK293 CellsHumansIndolesMaleimidesMicroscopy, ConfocalOrganic Cation Transporter 1Organic Cation Transporter 2Organic Cation Transport ProteinsProtein Kinase CTetraethylammoniumbisindolylmaleimideEnzyme InhibitorsGreen Fluorescent ProteinsIndolesMaleimidesOrganic Cation Transporter 1Organic Cation Transporter 2Organic Cation Transport ProteinsProtein Kinase CRo 31-8220ruboxistaurinSLC22A2 protein, humanSLC47A1 protein, humanSLC47A2 protein, humanTetraethylammonium

Identifiers

PMID26657401
PMCPMC4675551
OpenAlexW2288625737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.